Paragon Care Limited AI Stock Analysis
Want to see AU:PGC full AI Analyst Report?
Paragon Care Limited (PGC) AI Stock Analysis
Paragon Care Limited
(ASX:PGC)
The score is primarily held back by weak financial performance: margins compressed materially and earnings turned negative, with leverage rising and free cash flow still negative. Technicals provide partial support via improving short-term momentum, but the longer-term trend remains weaker. Valuation is constrained by the negative P/E, reflecting current losses and limiting confidence in earnings-based attractiveness.
Paragon Care Limited (PGC) vs. iShares MSCI Australia ETF (EWA)
- Market Cap
- AUD 264.85M
- Dividend Yield
- ―
- Average Volume (3M)
- 446.39K
- Price to Earnings (P/E)
- -16.1
- Beta (1Y)
- 0.86
- Revenue Growth
- 1.84%
- EPS Growth
- -178.23%
- Country
- Australia
- Employees
- 869
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Medical - Distribution
Paragon Care Limited Business Overview & Revenue Model
Company Description
Paragon Care Limited distributes medical equipment, devices, and consumable products in Australia, New Zealand, and Asia. The company designs, manufactures, and distributes reagent red blood cells, monoclonal blood grouping reagents, and ancillary pr...
Paragon Care Limited Financial Statement Overview
Summary
Despite strong recent revenue growth (+21.7% in 2025 and +33.3% in 2026), profitability weakened sharply: gross margin fell from 9.0% to 4.3%, EBIT margin was ~0.2%, and the company moved to a net loss in 2026 (net margin -0.4%). Leverage increased (debt-to-equity 0.93 to 1.31) and free cash flow remained negative in 2026 (-A$1.5m) after a deeply negative 2025, limiting financial flexibility.
Income Statement
38NegativeBalance Sheet
55NeutralCash Flow
42Neutral| Breakdown | TTM | Jun 2026 | Jun 2025 | Jun 2024 | Jun 2023 | Jun 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 3.68B | 3.68B | 3.61B | 2.97B | 307.63M | 237.62M |
| Gross Profit | 157.46M | 157.46M | 324.00M | 176.07M | 51.68M | 36.58M |
| EBITDA | 43.70M | 43.70M | 89.81M | 43.18M | 37.07M | 23.96M |
| Net Income | -16.03M | -16.03M | 20.57M | 8.38M | 12.80M | 6.63M |
Balance Sheet | ||||||
| Total Assets | 1.37B | 1.37B | 1.23B | 1.13B | 448.52M | 438.44M |
| Cash, Cash Equivalents and Short-Term Investments | 23.68M | 23.68M | 21.90M | 19.94M | 970.00K | 46.20M |
| Total Debt | 388.90M | 388.90M | 296.52M | 251.83M | 122.14M | 131.26M |
| Total Liabilities | 1.08B | 1.08B | 915.04M | 838.97M | 196.56M | 196.31M |
| Stockholders Equity | 295.88M | 295.88M | 319.00M | 291.92M | 18.88M | 235.82M |
Cash Flow | ||||||
| Free Cash Flow | -1.49M | -1.49M | -23.04M | 25.14M | -3.30M | 14.42M |
| Operating Cash Flow | 29.09M | 29.09M | -11.35M | 44.45M | 17.75M | 19.03M |
| Investing Cash Flow | -83.04M | -83.04M | -16.64M | -19.52M | -31.75M | 7.07M |
| Financing Cash Flow | 59.42M | 59.42M | 28.65M | -5.95M | -10.00M | -11.93M |
Paragon Care Limited Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AU:PGC, the sentiment is Positive. The current price of 0.16 is above the 20-day moving average (MA) of 0.15, above the 50-day MA of 0.15, and above the 200-day MA of 0.15, indicating a bullish trend. The MACD of 0.00 indicates Negative momentum. The RSI at 57.83 is Neutral, neither overbought nor oversold. The STOCH value of 100.00 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for AU:PGC.
Paragon Care Limited Peers Comparison
Overall Rating
AU:PNV71Outperform
AU:EPN67Neutral
AU:SIG61Neutral
AU:CMP54Neutral
AU:TRJ52Neutral
AU:PGC50Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| 71Outperform | AUD 576.85M | 77.12 | 8.45% | ― | 12.94% | -44.50% | |
| 67Neutral | AUD 9.73M | 83.33 | 3.34% | ― | 121.40% | ― | |
| 61Neutral | AUD 33.19B | 47.08 | 14.34% | 1.38% | ― | ― | |
| 54Neutral | AUD 46.94M | 209.09 | 0.93% | ― | 18.54% | ― | |
| 52Neutral | AUD 52.74M | -85.00 | -0.62% | ― | -3.05% | 86.01% | |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| 50Neutral | AUD 264.85M | -16.14 | -5.34% | ― | 1.84% | -178.23% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| AU:PGC | Paragon Care Limited | 0.16 | -0.14 | -47.54% | |
| AU:SIG | Sigma Healthcare Ltd | 2.89 | -0.02 | -0.55% | |
| AU:PNV | Polynovo Limited | 0.83 | -0.29 | -26.11% | |
| AU:CMP | Compumedics Limited | 0.23 | -0.09 | -27.69% | |
| AU:EPN | Epsilon Healthcare Limited | 0.03 | 0.00 | 4.17% | |
| AU:TRJ | Trajan Group Holdings Ltd | 0.34 | -0.31 | -46.92% |
Paragon Care Limited Corporate Events
Paragon Care shareholders carry three resolutions at 2026 AGM
At its 2026 Annual General Meeting on 18 November 2026, Paragon Care shareholders carried resolutions adopting the remuneration report, re-electing David Collins as a director and appointing the auditor. The remuneration report received 93.40% of vot...
ParagonCare reports 2026 integration completion, acquisitions and buy-back activity
ParagonCare said its 2026 financial year included completion of its 3-2-1 integration strategy, achievement of sales, EBITDA and net-debt guidance targets, six acquisitions across Asia and Australia/New Zealand, leadership transition completion, and...
Paragon Care Reports Lapse of 4.6 Million Performance Rights
Paragon Care Limited has disclosed that 4,590,505 performance rights with the ASX security code PGCAJ have lapsed. The lapse occurred because the conditional rights to these securities were not, or could no longer be, satisfied under the terms of the...
Paragon Care Plans Auditor Shift from EY to KPMG After Tender Review
Paragon Care has selected KPMG as its preferred external auditor following a competitive tender, with the appointment contingent on ASIC consent to Ernst & Young’s resignation and shareholder approval under the Corporations Act. The proposed change w...
Paragon Care Sets Out 2026 Governance and Diversity Framework
Paragon Care Limited has released its 2026 Corporate Governance Statement, outlining how its Board oversees strategy, risk and compliance across the Group in line with ASX Corporate Governance Council guidelines. The company details a formal Board Ch...
Paragon Care Files Updated Corporate Governance Statement with ASX
Paragon Care Limited has lodged its updated corporate governance statement for the year ended 30 June 2026, confirming it is available on the company’s website and current as of 23 September 2026. The accompanying Appendix 4G outlines that Paragon Ca...
Paragon Care Confirms FY26 Results With Unqualified Audit Opinion
Paragon Care Limited has released its audited financial results for the year ended 30 June 2026, confirming that profit after tax, comprehensive income and key balance sheet metrics are unchanged from the preliminary figures lodged in August. The com...
Paragon Care Launches On‑Market Share Buy‑Back of PGC Shares
Paragon Care Limited has notified the market of an on‑market share buy‑back of its ordinary fully paid shares, traded under the ASX code PGC. The announcement, lodged as a new notice with the Australian Securities Exchange, confirms the company’s int...
Paragon Care launches employee share purchases and $10.8m on-market buy-back
Paragon Care has directed its Employee Share Trust to purchase up to 23,900,401 ordinary shares on market to satisfy future vesting and grants under the company’s Employee Incentive Plan, with acquisitions governed by price caps, ASX notifications an...
Paragon Care Sets Date and Director Nomination Deadline for 2026 AGM
Paragon Care Limited has scheduled its 2026 Annual General Meeting for 1.00pm AEDT on 18 November 2026, with the meeting details to be set out in a notice to shareholders and the ASX in October. The company has also set 7 October 2026 as the deadline...
Paragon Care Corrects Typographical Errors in Preliminary Final Report
Paragon Care Limited, an Australian-listed healthcare supplier, provides a wide range of medical equipment, devices, consumables, pharmaceuticals and complementary healthcare products. It also manufactures blood bank diagnostic reagents, with operati...
Paragon Care Releases FY26 Results and Highlights Cultural Acknowledgement
Paragon Care Limited has released its financial results for the year ended 30 June 2026 and provided an investor presentation outlining its FY26 performance. While detailed financial metrics are not disclosed in the text provided, the release signals...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Aug 27, 2026
